Darien Sutton

1 month ago | medicalxpress.com | Darien Sutton |Lisa Lock |Robert Egan

Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram mitochondrial structure to silence immune responses and ensure successful viral reproduction. The findings, published in Nature Microbiology, reveal how the virus-encoded protein vBcl-2 can hijack a host enzyme called NM23-H2 to dismantle mitochondrial immune signaling, highlighting a new potential point of viral vulnerability that could be exploited through drug discovery.

Mar 21, 2025 | markets.financialcontent.com | Darien Sutton

Philadelphia, PA, March 21, 2025 (GLOBE NEWSWIRE) -- Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., in collaboration with scientists in the laboratory of Norbert Pardi, Ph.D., at the University of Pennsylvania Perelman School of Medicine and at the Pennsylvania-headquartered biotechnology company INOVIO, described a next-generation vaccination technology that combines plasmid DNA with a lipid nanoparticle (LNP) delivery system.

Feb 28, 2025 | bakersfield.marketminute.com | Darien Sutton

PHILADELPHIA, PA, Feb. 28, 2025 (GLOBE NEWSWIRE) -- The lab of Filippo Veglia, Ph.D., at The Wistar Institute has discovered a previously unknown mechanism for how aggressive brain cancers reprogram immune system cells from fighting cancer to enabling further tumor growth. The team’s findings were published in the paper “Functional reprogramming of neutrophils within the brain tumor microenvironment by hypoxia-driven histone lactylation,” from Cancer Discovery.

Feb 5, 2025 | morningstar.com | Darien Sutton

PHILADELPHIA, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- The lab of The Wistar Institute’s Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. The team published their findings in the paper, “Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPKi-resistant NRASMUT melanoma,” from the journal Science Translational Medicine.

Dec 3, 2024 | morningstar.com | Darien Sutton

PHILADELPHIA, PA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- PHILADELPHIA — (December 3, 2024) — The Wistar Institute’s David B. Weiner, Ph.D. — Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research — and his lab have successfully tested a new immune therapy that, in preclinical lab testing, reliably improves survival and reduces tumor burden in glioblastoma.